Medicine

Scientists are debating whether to delay, skip or halve doses. But untested tweaks could shake public confidence

In the U.S., a third of Americans are at risk of chronic kidney disease, and age is a major factor. More than half of Americans older than 75 are thought to have some sort of kidney damage. Here is what happens when you have it. Read the full five-part series in partnership with Undark: “Profit and Loss: America on Dialysis.”

The job of the oncologist of the future will be to prevent and treat the emergence of disease

Social science offers valuable lessons about ways to convince those who are hesitant about the shots

Companies are scrambling to obtain supplies for hundreds of millions of doses of a type of vaccine that has never been made at this scale before

There is evidence the new variant could be more transmissible, yet vaccines work very well against it

Two RNA vaccines will be useful as U.S. infections surge, but the speedy authorizations complicate clinical trials

Treatments that reduce suffering and incorporate patient values aren’t common in kidney disease care. That’s changing

Demand for healthy kidneys has long outstripped supply. But better testing and treatment are expanding the donor pool

Minority patients are diagnosed later, stay on dialysis longer and are added to transplant lists less quickly. Why?

Nurse Kristen Choi says health care providers need to better educate patients about possible side effects from the COVID-19 vaccine. Christopher Intagliata reports.

Joint ventures between nephrologists and dialysis centers have expanded treatment. Critics ask: At what cost?